Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors

Supportive Care in Cancer

Volumn 23, Issue 2, 2015, Pages 447-455

  Olufade, Temitope ^a,b   Gallicchio, Lisa ^a,b   MacDonald, Ryan ^a   Helzlsouer, Kathy J ^a,b  

^a MERCY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Health related quality of life; Musculoskeletal pain

Indexed keywords

AROMATASE INHIBITOR;

AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MIDDLE AGED; MUSCULOSKELETAL PAIN; PAIN MEASUREMENT; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84929663536     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2364-3     Document Type: Article

References (48)

1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76(1):27–36
2. Grana G (2004) Shifting paradigms in hormonal therapy for breast cancer. Cancer Biol Ther 3(9):797–805
3. Narashimamurthy J, Rao AR, Sastry GN (2004) Aromatase inhibitors: a new paradigm in breast cancer treatment. Curr Med Chem Anticancer Agents 4(6):523–534
4. Howell A (2005) Anastrozole: a new gold standard of hormonal treatment for breast cancer? Womens Health (Lond Engl) 1(3):309–322
5. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518
6. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108
7. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141
8. Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE et al (2008) Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 107(3):397–403
9. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH (2009) Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 115(10):2041–2051
10. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103(17):1299–1309
11. Duffy SR, Distler W, Howell A, Cuzick J, Baum M (2009) A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol 200(1):80.e1–e7
12. Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115(19):4442–4449
13. Khan QJ, O'Dea AP, Sharma P (2010) Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol pii: 654348
14. Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L et al (2011) Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther 11:1253–1263
15. Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13(2):205
16. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372
17. Park JY, Lee SK, Bae SY, Kim J, Kim MK, Kil WH et al (2013) Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc 85(5):205–211
18. Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L et al (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 4(12):1910–1918
19. Robidoux A, Rich E, Bureau NJ, Mader S, Laperrière D, Bail M et al (2011) A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy. Curr Oncol 18(6):285–294
20. Moxley G (2010) Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer 10(2):144–147
21. Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA et al (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer. doi:10.1037/ a0028240
22. Sueblinvong T, Taechakraichana N, Phupong V (2001) Prevalence of climacteric symptoms according to years after menopause. J Med Assoc Thai 84(12):1681–1691
23. Bairy L, Adiga S, Bhat P, Bhat R (2009) Prevalence of menopausal symptoms and quality of life after menopause in women from South India. Aust N Z J Obstet Gynaecol 49(1):106–109
24. Dugan SA, Powell LH, Kravitz HM, Everson Rose SA, Karavolos K, Luborsky J (2006) Musculoskeletal pain and menopausal status. Clin J Pain 22(4):325–331
25. Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, et al., Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 110:230–240
26. Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E (2012) A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 131(1):277–285
27. Tüzün EH (2007) Quality of life in chronic musculoskeletal pain.Best. Pract Res Clin Rheumatol 21(3):567–579
28. Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y et al (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 133(1):227–236
29. Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H et al (2011) Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03. Breast Cancer Res Treat 127:143–152
30. Buijs C, de Vries EG, Mourits MJ, Willemse PH (2008) The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev 34:640–655
31. Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC, Trial Steering Committee IES (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106:1062–1067
32. Cellar D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284
33. van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC et al (2012) Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 34:267–276
34. Ware JE, Sherbourne CD (1992) The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473–483
35. Stewart AL, Hays RD, Aare JE Jr (1988) The MOS Short-Form General Health Survey: reliability and validity in a patient population. Med Care 26:724–732
36. Okamoto T, Shimozuma K, Katsumata N, Koike M, Hisashige A, Tanaka K et al (2003) Task Force of the Japanese Breast Cancer Society for 'The Development of Guidelines for Quality of Life Assessment Studies of Breast Cancer Patients'. Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer 10:204–213
37. Pinar R (2005) Reliability and construct validity of the SF-36 in Turkish cancer patients. Qual Life Res 14:259–264
38. Paul SM, Zelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113:37–44
39. Jones KR, Vojir CP, Hutt E, Fink R (2007) Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents. J Rehabil Res Dev 44:305–314
40. Winters L, Habin K, Flanagan J, Cashavelly BJ (2010) "I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs 14:379–382
41. Vickberg SJ (2003) The Concerns About Recurrence Scale (CARS): a systematic measure of women’s fears about the possibility of breast cancer recurrence. Ann Behave Med 25:16–24
42. Lebel S, Rosberger Z, Edgar L, Devins GM (2009) Emotional distress impacts fear of the future among breast cancer survivors not the reverse. J Cancer Surviv 3:117–127
43. van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J (2008) Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology 17:1137–1145
44. Green CR, Hart-Johnson T, Loeffler DR (2011) Cancer-related chronic pain: examining quality of life in diverse cancer survivors. 117:1994–2003
45. Ashing Giwa KT, Lim JW (2011) Examining emotional outcomes among a multiethnic cohort of breast cancer survivors. Oncol Nurs Forum 38:279–288
46. Janz NK, Mujahid MS, Hawley ST, Griggs JJ, Alderman A, Hamilton AS, Graff J, Katz SJ (2009) Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv 3:212–222
47. Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR et al (2014) Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer 14(2):e21–e31
48. Bowen DJ, Alfano CM, McGregor BA, Kuniyuki A, Bernstein L, Meeske K et al (2007) Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. Breast Cancer Res Treat 106(1):85–95